BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 6167518)

  • 1. Serotype-nonspecific protection induced by ribonucleic acid isolated from the ribosomal vaccine of Pseudomonas aeruginosa.
    Gonggrijp R; Mullers WJ; van Boven CP
    Infect Immun; 1981 Jul; 33(1):178-85. PubMed ID: 6167518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective activities of ribosomal ribonucleic acid and lipopolysaccharide of Pseudomonas aeruginosa: a comparative study.
    Gonggrijp R; Mullers WJ; van Boven CP
    Antonie Van Leeuwenhoek; 1983 Jun; 49(2):173-82. PubMed ID: 6193755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of chickens by ribosomal vaccines from Pasteurella multocida: dependence on homologous lipopolysaccharide.
    Phillips M; Rimler RB
    Am J Vet Res; 1984 Sep; 45(9):1785-9. PubMed ID: 6208828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for the presence of lipopolysaccharide in a ribonuclease-sensitive ribosomal vaccine of Pseudomonas aeruginosa.
    Gonggrijp R; Volleberg MP; Lemmens PJ; van Boven CP
    Infect Immun; 1981 Mar; 31(3):896-905. PubMed ID: 6785242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribonuclease-sensitive ribosomal vaccines.
    Gonggrijp R; Antonissen AC; van den Bosch JF; van Boven CP
    Antonie Van Leeuwenhoek; 1984; 50(5-6):763-74. PubMed ID: 6084981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribonuclease-sensitive ribosomal vaccine of Pseudomonas aeruginosa.
    Gonggrijp R; Mullers WJ; Lemmens PJ; van Boven CP
    Infect Immun; 1980 Jan; 27(1):204-10. PubMed ID: 6153637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.
    Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB
    J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudomonas aeruginosa infection and vaccination in the rat.
    Kostiala AA
    J Med Microbiol; 1980 May; 13(2):201-12. PubMed ID: 6770090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions.
    Lieberman MM; McKissock DC; Wright GL
    Infect Immun; 1979 Feb; 23(2):509-21. PubMed ID: 106013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smooth lipopolysaccharide is the major protective antigen for mice in the surface extract from IATS serotype 6 contributing to the polyvalent Pseudomonas aeruginosa vaccine PEV.
    MacIntyre S; Lucken R; Owen P
    Infect Immun; 1986 Apr; 52(1):76-84. PubMed ID: 3082762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
    Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
    Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific and nonspecific protection of mice by Pseudomonas aeruginosa lipopolysaccharides.
    Marx A; Meitert E; Salageanu A; Olinescu A; Savulian C; Sima F; Chersulick E
    Zentralbl Bakteriol Mikrobiol Hyg A; 1987 Apr; 264(1-2):154-62. PubMed ID: 3115002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyvalent antisera to Pseudomonas ribosomal vaccines: protection of mice against clinically isolated strains.
    Lieberman MM; Wright GL; Wolcott KM; McKissock-Desoto DC
    Infect Immun; 1980 Aug; 29(2):489-93. PubMed ID: 6783532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Production and experimental testing of the polyvalency of corpuscular vaccine for the prevention of Pseudomonas aeruginosa infections II. Experimental testing of the immunogenicity of polyvalent corpuscular Pseudomonas aeruginosa vaccine].
    Moroz AF; Antsiferova NG; Radkevich SA; Mishina VS
    Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):74-80. PubMed ID: 6800165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.
    Matthews-Greer JM; Gilleland HE
    J Infect Dis; 1987 Jun; 155(6):1282-91. PubMed ID: 3033095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudomonas aeruginosa ribosomal vaccine. A comparison of the immunogenicity of vaccines from two different serotypes.
    Lieberman MM
    Antibiot Chemother (1971); 1989; 42():193-202. PubMed ID: 2512837
    [No Abstract]   [Full Text] [Related]  

  • 18. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
    Zaidi TS; Priebe GP; Pier GB
    Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomonas ribosomal vaccines: preparation, properties, and immunogenicity.
    Lieberman MM
    Infect Immun; 1978 Jul; 21(1):76-86. PubMed ID: 101464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.
    Kamei A; Coutinho-Sledge YS; Goldberg JB; Priebe GP; Pier GB
    Infect Immun; 2011 Mar; 79(3):1289-99. PubMed ID: 21149583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.